Wave Life Sciences’ stock soars 51% after biotech posts positive data from Duchenne muscular-dystrophy trial
Biotech reported positive interim data from a mid-stage trial of a treatment for the rare muscle disorder Duchenne muscular dystrophy.
Wave Life Sciences Stock Surges On Promising Interim Data From Mid-Stage Study Of Muscular Disorder Drug
Wave Life Sciences Ltd. (NASDAQ:WVE) revealed interim data from the ongoing Phase 2 FORWARD-53 study of WVE-N531 for Duchenne muscular dystrophy (DMD) patients amenable to exon 53 skipping. DMD is a genetic disease that causes progressive muscle weakness and degeneration caused by a mutation in the dystrophin gene.
Wave Life Sciences gains on data for Duchenne therapy
Wave Life Sciences (NASDAQ:WVE) added ~8% premarket Tuesday after the RNA therapeutics company announced interim data from a Phase 2 trial for WVE-N531, an experimental therapy for a neuromuscular disorder known as Duchenne muscular dystrophy (DMD).
Wave Life Sciences Shares Climb Premarket on Duchenne Study Data
Shares of Wave Life Sciences rose more than 10% in premarket trading Tuesday after the clinical-stage biotechnology company reported positive interim data from a mid-stage study of its WVE-N531 drug candidate in the neuromuscular genetic disease Duchenne muscular dystrophy.
Wave Life Sciences Ltd. (Nasdaq: WVE) Gains On Clinical Trial News
( MENAFN - Investor Ideas) Investorideas (), a go-to platform for big investing ideas for stock traders, including biotech Stocks reports on trading and news for Wave Life Sciences Ltd. (Nasdaq: WVE ), a clinical-stage biotechnology company focused on unlocking the broad potential of RNA medicines to transform human health.
Wave Life Sciences: Spiking On Strong DMD Data, But Not Fully De-Risked Yet
Wave Life Sciences stock surged over 50% today due to promising data from its Duchenne Muscular Dystrophy candidate WVE-N531. Explore more details here.
Wave Life Sciences’ WVE-N531 Shows Best-in-Class Potential in DMD Treatment, Justifying a Buy Rating
H.C. Wainwright analyst Andrew Fein has maintained their bullish stance on WVE stock, giving a Buy rating yesterday. Andrew Fein has given his ...
FierceBiotech9h
Wave surfs DMD success to regulators' doors, sending stock up
Wave’s result is in line with the data that supported accelerated approval of NS Pharma’s exon 53 DMD drug Viltepso. NS ...
Crude Oil Gains Over 1%; BioVie Shares Plunge
BioVie Inc. BIVI shares dropped 56% to $1.2399 after the company announced it raised $3 million through a secondary offering ...
Buy Rating on Wave Life Sciences: Undervalued DMD Program and Promising Data Offer Investment Upside
Analyst Tiago Fauth from Wells Fargo maintained a Buy rating on Wave Life Sciences (WVE – Research Report) and keeping the price target ...
FrontView REIT seeks to raise up to $277 million in US IPO
FrontView REIT is aiming to raise as much as $277.2 million in its initial public offering in the United States, it said on ...
Nasdaq Surges 100 Points; Thor Industries Earnings Top Views
European shares were higher today. The eurozone's STOXX 600 rose 0.58%, Germany's DAX gained 0.63% and France's CAC 40 gained ...